Mitsubishi Tanabe Pharma Corporation

Type: Company
Name: Mitsubishi Tanabe Pharma Corporation
First reported Oct 01 2014 - Updated 17 hours ago - 1 reports

ANALYSIS-Plant-based vaccines challenge big pharma for $3 billion flu market

NEW YORK, Oct. 1 (Reuters) - Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.The ... [Published CNBC - Oct 01 2014]
Entities: Vaccine, Influenza, Medicago
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Global Hyperglycemia Therapeutics Pipeline Review - H2 2014: 3 Companies and 11 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/mk64nx/hyperglycemia) has announced the addition of the "Hyperglycemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic ... [Published Individual.com - Sep 24 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Mitsubishi Tanabe receives approval for additional indication of HCV drug

Mitsubishi Tanabe Pharma Corporation has received approval for an additional indication of TELAVIC 250mg tablets, indicated for the treatment of chronic genotype 2 hepatitis C virus infection, or HCV. Telavic, an oral treatment of chronic hepatitis C, ... [Published Individual.com - Sep 23 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Global Generic Drugs Market 2014-2018

Portland, OR -- ( ReleaseWire ) -- 09/22/2014 -- TechNavio's analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing ... [Published SBWire - Sep 22 2014]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

VIVUS and Auxilium Announce Stendra Label...

Stendra, a phosphodiesterase type 5 (PDE5) inhibitor, received marketing approval in the U.S. in Apr 2012 and the EU in Jun 2013. VIVUS has collaborated for the drug with privately -held Italian pharmaceutical company, Menarini (more than 40 European ... [Published Nasdaq - Sep 20 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Vivus, Inc. Opens Sharply Higher On ED Drug Marketing Approval

Vivus Inc. (NASDAQ: VVUS) shares rose sharply in pre-market activity after its fast-acting erectile dysfunction drug won marketing approval Thursday from federal regulators.The drug, avanafil, can be effective when taken as early as 15 minutes before ... [Published Benzinga.com - Sep 18 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Vivus And Auxilium Pharma Say FDA Approves SNDA For Stendra - Quick Facts

Vivus Inc. (VVUS: Quote) and Auxilium Pharmaceuticals, Inc. (AUXL: Quote) announced that the U.S. Food and Drug Administration or FDA has approved a supplemental new drug application or sNDA for Stendra (avanafil).The companies said that STENDRA is now ... [Published RTTNews.com - Sep 18 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Novartis Presents Data on Multiple Sclerosis Drug Gilenya

Novartis ( NVS - Analyst Report ) presented encouraging data on multiple sclerosis (MS) drug, Gilenya, from a follow-up extension study, LONGTERMS, at the Joint ACTRIMS-ECTRIMS Meeting in Boston. Gilenya was seen to sustain its efficacy in treating ... [Published Zacks.com - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

AstraZeneca to present diabetes drug data in Vienna

iNVEZZ.com, Wednesday, September 10: AstraZeneca Plc (LON:AZN) will present data for several diabetes drugs at an upcoming event in Vienna, the Anglo-Swedish drugmaker has said. The abstracts are expected to cover some of the company’s approved products ... [Published Invezz - Sep 10 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

AstraZeneca And Redx Ink R&D Deal On Tumor Genetics

By Estel Grace MasangkayBritish drug firm AstraZeneca and Redx Pharma announced that they have signed into a research collaboration to discover and develop new molecules that will combat a genetic driver of tumor survival and growth.As part of the agreement, ... [Published Bioresearch Online - Sep 05 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

AstraZeneca and MTPC announce research collaboration in diabetic nephropathy

AstraZeneca and Mitsubishi Tanabe Pharma Corporation, or MTPC, have announced three-year research collaboration in the area of diabetic nephropathy. The aim of the research collaboration is to leverage complementary strengths, expertise and assets to ... [Published Individual.com - Sep 05 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan

--- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") today announced the initiation of a phase 2b clinical study evaluating KHK7580 for secondary hyperparathyroidism patients receiving hemodialysis in Jap ... [Published Noodls - Aug 29 2014]

Quotes

"Today, all of our flu-vaccine production is in (chicken) eggs," said Rene Labutat, vice-president of manufacturing for Sanofi. "But we are looking at the recombinant approach, including in mammalian cells, algae, fungi and plants."
...and offers men and their partners an exciting new option," said Adrian Adams, chief executive officer and president of Auxilium Pharmaceuticals. "We believe this label expansion helps position Stendra as an exciting 'on demand' ED treatment and assists with the very important aspect of spontaneity for men and their partners in real world use. We believe this provides a meaningful benefit for men with ED and further underscores Auxilium's commitment to being an innovative leader in men's healthcare."
"MTPC is now focusing its drug discovery research efforts and multifaceted translational research, including collaboration with Kyoto University Hospital and TMK project, to developing new treatments for chronic kidney disease patients. We expect the new collaboration with AstraZeneca will strengthen the expertise of both companies in this area and accelerate the delivery of new medicines for patients with diabetic nephropathy" said Takashi Kobayashi, Division manager of Research division, MTPC
"Our interest in Covagen stems from the company's scientific acumen, their novel FynomAb platform, and the potential of COVA 322, a bispecific designed to achieve better control of inflammation by blocking two key cytokines that have been implicated in disease pathogenesis and progression,” said Susan B Dillon, Ph D , global therapeutic area head of immunology, Janssen Research & Development. “We look forward to progressing COVA 322 development, and to further expanding the potential of multispecific biologics for immunologic and other diseases.”"

More Content

All (22) | News (20) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
ANALYSIS-Plant-based vaccines challenge big pha... [Published CNBC - Oct 01 2014]
Global Hyperglycemia Therapeutics Pipeline Revi... [Published Individual.com - Sep 24 2014]
Mitsubishi Tanabe receives approval for additio... [Published Individual.com - Sep 23 2014]
SADIF Analytics releases new summary due dilige... [Published PR inside - Sep 23 2014]
Global Generic Drugs Market 2014-2018 [Published SBWire - Sep 22 2014]
US FDA approves Stendra for erectile dysfunctio... [Published PharmaBiz - Sep 20 2014]
VIVUS and Auxilium Announce Stendra Label... [Published Nasdaq - Sep 20 2014]
VIVUS and Auxilium Announce Stendra Label Expan... [Published Zacks.com - Sep 19 2014]
Vivus, Inc. Opens Sharply Higher On ED Drug Mar... [Published Yahoo! Finance - Sep 18 2014]
Vivus, Inc. Opens Sharply Higher On ED Drug Mar... [Published Benzinga.com - Sep 18 2014]
Vivus And Auxilium Pharma Say FDA Approves SNDA... [Published RTTNews.com - Sep 18 2014]
Novartis Presents Data on Multiple Sclerosis Dr... [Published Zacks.com - Sep 11 2014]
AstraZeneca to present diabetes drug data in Vi... [Published Invezz - Sep 10 2014]
AstraZeneca And Redx Ink R&D Deal On Tumor Gene... [Published Bioresearch Online - Sep 05 2014]
AstraZeneca and MTPC announce research collabor... [Published Individual.com - Sep 05 2014]
Mitsubishi Chemical Holdings Shelf Reg.: R&I As... [Published Noodls - Sep 01 2014]
Dezima Reports Positive Results in its Phase 2b... [Published CEOWorld Magazine - Aug 29 2014]
Kyowa Hakko Kirin Announces Commencement of Pha... [Published Noodls - Aug 29 2014]
Janssen Affiliate Cilag Acquires Covagen [Published Genetic Engineering News - Aug 25 2014]
Invokamet approved in US to treat adults with t... [Published PharmaBiz - Aug 11 2014]
Fact Sheet for Mitsubishi Chemical Holdings Corp [Published Silobreaker - Feb 05 2010]
Fact Sheet for Mitsubishi Chemical Holdings Cor... [Published Able2Act - Dec 28 2007]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.